Mitochondrial Abnormalities in Alzheimer's Disease. Possible Targets for Therapeutic Intervention

Advances in Pharmacology

Volumn 64, Issue , 2012, Pages 83-126

  Silva, Diana F ^a,b   Selfridge, J Eva ^a   Lu, Jianghua ^a   E, Lezi ^a   Cardoso, Sandra M ^b   Swerdlow, Russell H ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Aging; Alzheimer's disease; Bioenergetics; Cybrids; Mitochondria; Therapeutics

Indexed keywords

DAVUNETIDE; DIMEBON; MITOCHONDRIAL DNA; MITOCHONDRIAL ENZYME;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; BIOENERGY; CLINICAL ASSESSMENT; CYBRID; CYTOSKELETON; ELECTRON TRANSPORT; ENDOPHENOTYPE; EPIDEMIOLOGICAL DATA; GENE TARGETING; HUMAN; MITOCHONDRIAL DNA DISORDER; MORPHOLOGY; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK ASSESSMENT; SYMPTOM;

EID: 84864385007     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394816-8.00003-9     Document Type: Chapter

References (298)

1. Aksenov M.Y., Tucker H.M., Nair P., Aksenova M.V., Butterfield D.A., Estus S., et al. The expression of several mitochondrial and nuclear genes encoding the subunits of electron transport chain enzyme complexes, cytochrome c oxidase, and NADH dehydrogenase, in different brain regions in Alzheimer's disease. Neurochemical Research 1999, 24(6):767-774.
2. Albrecht S., Bourdeau M., Bennett D., Mufson E.J., Bhattacharjee M., LeBlanc A.C. Activation of caspase-6 in aging and mild cognitive impairment. American Journal of Pathology 2007, 170(4):1200-1209.
3. Aliev G., Palacios H.H., Walrafen B., Lipsitt A.E., Obrenovich M.E., Morales L. Brain mitochondria as a primary target in the development of treatment strategies for Alzheimer disease. International Journal of Biochemistry & Cell Biology 2009, 41(10):1989-2004.
4. Aluise C.D., Robinson R.A., Cai J., Pierce W.M., Markesbery W.R., Butterfield D.A. Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer's disease: Insights into memory loss in MCI. Journal of Alzheimer's Disease 2011, 23(2):257-269.
5. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie Psych-Gerichtl Med 1907, 64:146-148.
6. Alzheimer A. Uber eigenartige Krankheitsfalle des spateren Alters. Zeitschrift für die gesamte Neurologie und Psychiatrie 1911, 4:456-485.
7. Alzheimer A., Stelzmann R.A., Schnitzlein H.N., Murtagh F.R. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde" Clinical Anatomy 1995, 8(6):429-431.
8. Ames B.N., Shigenaga M.K., Hagen T.M. Mitochondrial decay in aging. Biochimica et Biophysica Acta 1995, 1271(1):165-170.
9. Anderson A.J., Su J.H., Cotman C.W. DNA damage and apoptosis in Alzheimer's disease: Colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay. Journal of Neuroscience 1996, 16(5):1710-1719.
10. Anekonda T.S., Reddy P.H. Neuronal protection by sirtuins in Alzheimer's disease. Journal of Neurochemistry 2006, 96(2):305-313.
11. Ansari M.A., Scheff S.W. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. Journal of Neuropathology and Experimental Neurology 2010, 69(2):155-167.
12. Arduino D.M., Esteves A.R., Cardoso S.M. Mitochondrial fusion/fission, transport and autophagy in Parkinson's disease: when mitochondria get nasty. Parkinsons's Disease 2011, 2011:767230.
13. Atamna H., Kumar R. Protective role of methylene blue in Alzheimer's disease via mitochondria and cytochrome c oxidase. Journal of Alzheimer's Disease 2010, 2(Suppl. 20):S439-S452.
14. Atamna H., Nguyen A., Schultz C., Boyle K., Newberry J., Kato H., et al. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB Journal 2008, 22(3):703-712.
15. Avila J. Alzheimer disease: Caspases first. Nature Reviews. Neurology 2010, 6(11):587-588.
16. Ayala-Grosso C., Tam J., Roy S., Xanthoudakis S., Da Costa D., Nicholson D.W., et al. Caspase-3 cleaved spectrin colocalizes with neurofilament-immunoreactive neurons in Alzheimer's disease. Neuroscience 2006, 141(2):863-874.
17. Baar K., Wende A.R., Jones T.E., Marison M., Nolte L.A., Chen M., et al. Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1. FASEB Journal 2002, 16(14):1879-1886.
18. Bachurin S.O., Shevtsova E.P., Kireeva E.G., Oxenkrug G.F., Sablin S.O. Mitochondria as a target for neurotoxins and neuroprotective agents. Annals of the New York Academy of Sciences 2003, 993:334-344. discussion 345-339.
19. Balaban R.S., Nemoto S., Finkel T. Mitochondria, oxidants, and aging. Cell 2005, 120(4):483-495.
20. Baldeiras I., Santana I., Proenca M.T., Garrucho M.H., Pascoal R., Rodrigues A., et al. Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease. Journal of Alzheimer's Disease 2008, 15(1):117-128.
21. Baloyannis S.J. Mitochondrial alterations in Alzheimer's disease. Journal of Alzheimer's Disease 2006, 9(2):119-126.
22. Baloyannis S.J. Mitochondria are related to synaptic pathology in Alzheimer's disease. International Journal of Alzheimer's Disease 2011, 2011:305395.
23. Barinaga M. Is apoptosis key in Alzheimer's disease?. Science 1998, 281(5381):1303-1304.
24. Barrett M.J., Alones V., Wang K.X., Phan L., Swerdlow R.H. Mitochondria-derived oxidative stress induces a heat shock protein response. Journal of Neuroscience Research 2004, 78(3):420-429.
25. Barsoum M.J., Yuan H., Gerencser A.A., Liot G., Kushnareva Y., Graber S., et al. Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons. EMBO Journal 2006, 25(16):3900-3911.
26. Baur J.A. Biochemical effects of SIRT1 activators. Biochimica et Biophysica Acta 2010, 1804(8):1626-1634.
27. Behl C. Apoptosis and Alzheimer's disease. Journal of Neural Transmission 2000, 107(11):1325-1344.
28. Bermejo P., Martin-Aragon S., Benedi J., Susin C., Felici E., Gil P., et al. Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from Mild Cognitive Impairment. Free Radical Research 2008, 42(2):162-170.
29. Berti V., Mosconi L., Glodzik L., Li Y., Murray J., De Santi S., et al. Structural brain changes in normal individuals with a maternal history of Alzheimer's. Neurobiology of Aging 2011, Epub ahead of print.
30. Bjelakovic G., Nikolova D., Gluud L.L., Simonetti R.G., Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. The Journal of the American Medical Association 2007, 297(8):842-857.
31. Blass J.P., Gibson G.E. Correlations of disability and biologic alterations in Alzheimer brain and test of significance by a therapeutic trial in humans. Journal of Alzheimer's Disease 2006, 9(2):207-218.
32. Blass J.P., Sheu K.F., Piacentini S., Sorbi S. Inherent abnormalities in oxidative metabolism in Alzheimer's disease: interaction with vascular abnormalities. Annals of the New York Academy of Sciences 1997, 826:382-385.
33. Blocq P., Marinesco G. Sur les lesions et la pathogenie de l'epilepsie dite essentielle. La Semaine Medicale 1892, 12:445-446.
34. Boland B., Kumar A., Lee S., Platt F.M., Wegiel J., Yu W.H., et al. Autophagy induction and autophagosome clearance in neurons: Relationship to autophagic pathology in Alzheimer's disease. Journal of Neuroscience 2008, 28(27):6926-6937.
35. Bolognesi M.L., Matera R., Minarini A., Rosini M., Melchiorre C. Alzheimer's disease: New approaches to drug discovery. Current Opinion in Chemical Biology 2009, 13(3):303-308.
36. Bonda D.J., Wang X., Perry G., Nunomura A., Tabaton M., Zhu X., et al. Oxidative stress in Alzheimer disease: A possibility for prevention. Neuropharmacology 2010, 59(4-5):290-294.
37. Broe M., Shepherd C.E., Milward E.A., Halliday G.M. Relationship between DNA fragmentation, morphological changes and neuronal loss in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathologica 2001, 101(6):616-624.
38. Brown A.M., Sheu R.K., Mohs R., Haroutunian V., Blass J.P. Correlation of the clinical severity of Alzheimer's disease with an aberration in mitochondrial DNA (mtDNA). Journal of Molecular Neuroscience 2001, 16(1):41-48.
39. Bubber P., Haroutunian V., Fisch G., Blass J.P., Gibson G.E. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Annals of Neurology 2005, 57(5):695-703.
40. Burns D.H., Rosendahl S., Bandilla D., Maes O.C., Chertkow H.M., Schipper H.M. Near-infrared spectroscopy of blood plasma for diagnosis of sporadic Alzheimer's disease. Journal of Alzheimer's Disease 2009, 17(2):391-397.
41. Butler D., Bendiske J., Michaelis M.L., Karanian D.A., Bahr B.A. Microtubule-stabilizing agent prevents protein accumulation-induced loss of synaptic markers. European Journal of Pharmacology 2007, 562(1-2):20-27.
42. Butterfield D.A., Hensley K., Cole P., Subramaniam R., Aksenov M., Aksenova M., et al. Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: Relevance to Alzheimer's disease. Journal of Neurochemistry 1997, 68(6):2451-2457.
43. Butterfield D.A., Lange M.L. Multifunctional roles of enolase in Alzheimer's disease brain: Beyond altered glucose metabolism. Journal of Neurochemistry 2009, 111(4):915-933.
44. Butterfield D.A., Poon H.F., St Clair D., Keller J.N., Pierce W.M., Klein J.B., et al. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiology of Disease 2006, 22(2):223-232.
45. Butterfield D.A., Reed T., Perluigi M., De Marco C., Coccia R., Cini C., et al. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neuroscience Letters 2006, 397(3):170-173.
46. Butterfield D.A., Reed T.T., Perluigi M., De Marco C., Coccia R., Keller J.N., et al. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Research 2007, 1148:243-248.
47. Buttke T.M., Sandstrom P.A. Oxidative stress as a mediator of apoptosis. Immunology Today 1994, 15(1):7-10.
48. Calkins M.J., Manczak M., Mao P., Shirendeb U., Reddy P.H. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Human Molecular Genetics 2011, 20(23):4515-4529.
49. Calkins M.J., Reddy P.H. Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer's disease neurons. Biochimica et Biophysica Acta 2011, 1812(4):507-513.
50. Callaway N.L., Riha P.D., Bruchey A.K., Munshi Z., Gonzalez-Lima F. Methylene blue improves brain oxidative metabolism and memory retention in rats. Pharmacology, Biochemistry, and Behavior 2004, 77(1):175-181.
51. Cardoso S.M., Pereira C.F., Moreira P.I., Arduino D.M., Esteves A.R., Oliveira C.R. Mitochondrial control of autophagic lysosomal pathway in Alzheimer's disease. Experimental Neurology 2010, 223(2):294-298.
52. Cardoso S.M., Proenca M.T., Santos S., Santana I., Oliveira C.R. Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiology of Aging 2004, 25(1):105-110.
53. Cash A.D., Aliev G., Siedlak S.L., Nunomura A., Fujioka H., Zhu X., et al. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. American Journal of Pathology 2003, 162(5):1623-1627.
54. Castegna A., Aksenov M., Aksenova M., Thongboonkerd V., Klein J.B., Pierce W.M., et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: Creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radical Biology & Medicine 2002, 33(4):562-571.
55. Castegna A., Aksenov M., Thongboonkerd V., Klein J.B., Pierce W.M., Booze R., et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: Dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. Journal of Neurochemistry 2002, 82(6):1524-1532.
56. Chan D.C. Mitochondria: dynamic organelles in disease, aging, and development. Cell 2006, 125(7):1241-1252.
57. Chan D.C. Mitochondrial fusion and fission in mammals. Annual Review of Cell and Developmental Biology 2006, 22:79-99.
58. Chandrasekaran K., Giordano T., Brady D.R., Stoll J., Martin L.J., Rapoport S.I. Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer disease. Brain Research. Molecular Brain Research 1994, 24(1-4):336-340.
59. Chang S.W., Zhang D., Chung H.D., Zassenhaus H.P. The frequency of point mutations in mitochondrial DNA is elevated in the Alzheimer's brain. Biochemical and Biophysical Research Communications 2000, 273(1):203-208.
60. Chaturvedi R.K., Beal M.F. Mitochondrial approaches for neuroprotection. Annals of the New York Academy of Sciences 2008, 1147:395-412.
61. Chen H., McCaffery J.M., Chan D.C. Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell 2007, 130(3):548-562.
62. Cho D.H., Nakamura T., Fang J., Cieplak P., Godzik A., Gu Z., et al. S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science 2009, 324(5923):102-105.
63. Civitarese A.E., Smith S.R., Ravussin E. Diet, energy metabolism and mitochondrial biogenesis. Current Opinion in Clinical Nutrition and Metabolic Care 2007, 10(6):679-687.
64. Colurso G.J., Nilson J.E., Vervoort L.G. Quantitative assessment of DNA fragmentation and beta-amyloid deposition in insular cortex and midfrontal gyrus from patients with Alzheimer's disease. Life Science 2003, 73(14):1795-1803.
65. Conte V., Uryu K., Fujimoto S., Yao Y., Rokach J., Longhi L., et al. Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. Journal of Neurochemistry 2004, 90(3):758-764.
66. Corral-Debrinski M., Horton T., Lott M.T., Shoffner J.M., McKee A.C., Beal M.F., et al. Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. Genomics 1994, 23(2):471-476.
67. Coskun P.E., Beal M.F., Wallace D.C. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(29):10726-10731.
68. Coskun P.E., Wyrembak J., Derbereva O., Melkonian G., Doran E., Lott I.T., et al. Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia. Journal of Alzheimer's Disease 2010, 2(Suppl. 20):S293-S310.
69. Cottrell D.A., Blakely E.L., Johnson M.A., Ince P.G., Turnbull D.M. Mitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD. Neurology 2001, 57(2):260-264.
70. Cribbs D.H., Poon W.W., Rissman R.A., Blurton-Jones M. Caspase-mediated degeneration in Alzheimer's disease. American Journal of Pathology 2004, 165(2):353-355.
71. Cudkowicz M., Bozik M.E., Ingersoll E.W., Miller R., Mitsumoto H., Shefner J., et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nature Medicine 2011, 17(12):1652-1656.
72. Cuervo A.M. Autophagy: many paths to the same end. Molecular and Cellular Biochemistry 2004, 263(1-2):55-72.
73. Curti D., Rognoni F., Gasparini L., Cattaneo A., Paolillo M., Racchi M., et al. Oxidative metabolism in cultured fibroblasts derived from sporadic Alzheimer's disease (AD) patients. Neuroscience Letters 1997, 236(1):13-16.
74. Dai J., Buijs R.M., Kamphorst W., Swaab D.F. Impaired axonal transport of cortical neurons in Alzheimer's disease is associated with neuropathological changes. Brain Research 2002, 948(1-2):138-144.
75. de la Monte S.M., Luong T., Neely T.R., Robinson D., Wands J.R. Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease. Laboratory Investigation 2000, 80(8):1323-1335.
76. De Vos K.J., Chapman A.L., Tennant M.E., Manser C., Tudor E.L., Lau K.F., et al. Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Human Molecular Genetics 2007, 16(22):2720-2728.
77. Debette S., Wolf P.A., Beiser A., Au R., Himali J.J., Pikula A., et al. Association of parental dementia with cognitive and brain MRI measures in middle-aged adults. Neurology 2009, 73(24):2071-2078.
78. Detmer S.A., Chan D.C. Functions and dysfunctions of mitochondrial dynamics. Nature Reviews. Molecular Cell Biology 2007, 8(11):870-879.
79. Divinski I., Mittelman L., Gozes I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. Journal of Biological Chemistry 2004, 279(27):28531-28538.
80. Divry P. Etude histochimique des plaques seniles. Journal of Belge Neurology Psychiatry 1927, 9:643-657.
81. Doody R.S., Gavrilova S.I., Sano M., Thomas R.G., Aisen P.S., Bachurin S.O., et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008, 372(9634):207-215.
82. Ebneth A., Godemann R., Stamer K., Illenberger S., Trinczek B., Mandelkow E. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. Journal of Cell Biology 1998, 143(3):777-794.
83. Eckert A., Oster M., Zerfass R., Hennerici M., Muller W.E. Elevated levels of fragmented DNA nucleosomes in native and activated lymphocytes indicate an enhanced sensitivity to apoptosis in sporadic Alzheimer's disease. Specific differences to vascular dementia. Dementia and Geriatric Cognitive Disorders 2001, 12(2):98-105.
84. Evans D.A., Funkenstein H.H., Albert M.S., Scherr P.A., Cook N.R., Chown M.J., et al. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. The Journal of the American Medical Association 1989, 262(18):2551-2556.
85. Facchinetti F., Dawson V.L., Dawson T.M. Free radicals as mediators of neuronal injury. Cellular and Molecular Neurobiology 1998, 18(6):667-682.
86. Feinendegen L.E. Reactive oxygen species in cell responses to toxic agents. Human & Experimental Toxicology 2002, 21(2):85-90.
87. Fischer O. Miliare Nekrosen mit drusigen Wucherungen der Neurofibrillen, eine regelmabige Veranderung der Hirnrinde bei seniler Demenz. Monatsschrift für Psychiatrie und Neurologie 1907, 22:361-372.
88. Fukui H., Moraes C.T. The mitochondrial impairment, oxidative stress and neurodegeneration connection: Reality or just an attractive hypothesis?. Trends in Neurosciences 2008, 31(5):251-256.
89. Gabbita S.P., Lovell M.A., Markesbery W.R. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. Journal of Neurochemistry 1998, 71(5):2034-2040.
90. Geldmacher D.S., Fritsch T., McClendon M.J., Landreth G. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Archives of Neurology 2011, 68(1):45-50.
91. Ghosh S., Patel N., Rahn D., McAllister J., Sadeghi S., Horwitz G., et al. The thiazolidinedione pioglitazone alters mitochondrial function in human neuron-like cells. Molecular Pharmacology 2007, 71(6):1695-1702.
92. Gibson G.E., Sheu K.F., Blass J.P. Abnormalities of mitochondrial enzymes in Alzheimer disease. Journal of Neural Transmission 1998, 105(8-9):855-870.
93. Gibson G.E., Starkov A., Blass J.P., Ratan R.R., Beal M.F. Cause and consequence: Mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. Biochimica et Biophysica Acta 2010, 1802(1):122-134.
94. Glenner G.G., Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochemical and Biophysical Research Communications 1984, 120(3):885-890.
95. Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991, 349(6311):704-706.
96. Gold M., Alderton C., Zvartau-Hind M., Egginton S., Saunders A.M., Irizarry M., et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: Results from a randomized, double-blind, placebo-controlled phase III study. Dementia and Geriatric Cognitive Disorders 2010, 30(2):131-146.
97. Gordon P.H., Moore D.H., Miller R.G., Florence J.M., Verheijde J.L., Doorish C., et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomised trial. Lancet Neurology 2007, 6(12):1045-1053.
98. Gozes I., Divinski I. The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection. Journal of Alzheimer's Disease 2004, 6(Suppl. 6):S37-S41.
99. Gozes I., Divinski I. NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Current Alzheimer Research 2007, 4(5):507-509.
100. Gozes I., Morimoto B.H., Tiong J., Fox A., Sutherland K., Dangoor D., et al. NAP: Research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Reviews 2005, 11(4):353-368.
101. Gozes I., Stewart A., Morimoto B., Fox A., Sutherland K., Schmeche D. Addressing Alzheimer's disease tangles: From NAP to AL-108. Current Alzheimer Research 2009, 6(5):455-460.
102. Greggio S., de Paula S., de Oliveira I.M., Trindade C., Rosa R.M., Henriques J.A., et al. NAP prevents acute cerebral oxidative stress and protects against long-term brain injury and cognitive impairment in a model of neonatal hypoxia-ischemia. Neurobiology of Disease 2011, 44(1):152-159.
103. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proceedings of the National Academy of Sciences of the United States of America 1986, 83(13):4913-4917.
104. Guarente L. Sirtuins in aging and disease. Cold Spring Harbor Symposia on Quantitative Biology 2007, 72:483-488.
105. Guo H., Albrecht S., Bourdeau M., Petzke T., Bergeron C., LeBlanc A.C. Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease. American Journal of Pathology 2004, 165(2):523-531.
106. Hager K., Kenklies M., McAfoose J., Engel J., Munch G. Alpha-lipoic acid as a new treatment option for Alzheimer's disease - a 48 months follow-up analysis. Journal of Neural Transmission. Supplementum, 72 2007, 189-193.
107. Hager K., Marahrens A., Kenklies M., Riederer P., Munch G. Alpha-lipoic acid as a new treatment option for Alzheimer [corrected] type dementia. Archives of Gerontology and Geriatrics 2001, 32(3):275-282.
108. Haigis M.C., Guarente L.P. Mammalian sirtuins - emerging roles in physiology, aging, and calorie restriction. Genes & Development 2006, 20(21):2913-2921.
109. Hamblet N.S., Castora F.J. Elevated levels of the Kearns-Sayre syndrome mitochondrial DNA deletion in temporal cortex of Alzheimer's patients. Mutation Research 1997, 379(2):253-262.
110. Hansford R.G., Hogue B.A., Mildaziene V. Dependence of H2O2 formation by rat heart mitochondria on substrate availability and donor age. Journal of Bioenergetics and Biomembranes 1997, 29(1):89-95.
111. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends in Pharmacological Sciences 1991, 12(10):383-388.
112. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002, 297(5580):353-356.
113. Henderson S.T., Vogel J.L., Barr L.J., Garvin F., Jones J.J., Costantini L.C. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: A randomized, double-blind, placebo-controlled, multicenter trial. Nutrition & Metabolism 2009, 6:31.
114. Hirai K., Aliev G., Nunomura A., Fujioka H., Russell R.L., Atwood C.S., et al. Mitochondrial abnormalities in Alzheimer's disease. Journal of Neuroscience 2001, 21(9):3017-3023.
115. Hollenbeck P.J., Saxton W.M. The axonal transport of mitochondria. Journal of Cell Science 2005, 118(Pt 23):5411-5419.
116. Holloszy J.O., Coyle E.F. Adaptations of skeletal muscle to endurance exercise and their metabolic consequences. Journal of Applied Physiology 1984, 56(4):831-838.
117. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372(9634):216-223.
118. Honea R.A., Swerdlow R.H., Vidoni E., Burns J.M. Progressive regional atrophy in normaladults with a maternal history of Alzheimer disease. Neurology 2011, 76:822-829.
119. Honea R.A., Swerdlow R.H., Vidoni E.D., Goodwin J., Burns J.M. Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease. Neurology 2010, 74(2):113-120.
120. Hood D.A. Mechanisms of exercise-induced mitochondrial biogenesis in skeletal muscle. Applied Physiology, Nutrition, and Metabolism 2009, 34(3):465-472.
121. Hoppins S., Lackner L., Nunnari J. The machines that divide and fuse mitochondria. Annual Review of Biochemistry 2007, 76:751-780.
122. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274(5284):99-102.
123. Idan-Feldman A., Schirer Y., Polyzoidou E., Touloumi O., Lagoudaki R., Grigoriadis N.C., et al. Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model. Neurobiology of Disease 2011, 44(3):327-339.
124. Inoue M., Sato E.F., Nishikawa M., Park A.M., Kira Y., Imada I., et al. Mitochondrial generation of reactive oxygen species and its role in aerobic life. Current Medicinal Chemistry 2003, 10(23):2495-2505.
125. Ishihara N., Nomura M., Jofuku A., Kato H., Suzuki S.O., Masuda K., et al. Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in mice. Nature Cell Biology 2009, 11(8):958-966.
126. Javitt D.C., Buchanan R.W., Keefe R.S., Kern R., McMahon R.P., Green M.F., et al. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res 2012, 136(1-3):25-31.
127. Ji L.L. Antioxidants and oxidative stress in exercise. Proceedings of the Society for Experimental Biology and Medicine 1999, 222(3):283-292.
128. Kamat C.D., Gadal S., Mhatre M., Williamson K.S., Pye Q.N., Hensley K. Antioxidants in central nervous system diseases: preclinical promise and translational challenges. Journal of Alzheimer's Disease 2008, 15(3):473-493.
129. Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.H., et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325(6106):733-736.
130. Katzman R. Editorial: The prevalence and malignancy of Alzheimer disease. A major killer. Archives of Neurology 1976, 33(4):217-218.
131. Kawamoto E.M., Munhoz C.D., Glezer I., Bahia V.S., Caramelli P., Nitrini R., et al. Oxidative state in platelets and erythrocytes in aging and Alzheimer's disease. Neurobiology of Aging 2005, 26(6):857-864.
132. Keller J.N., Schmitt F.A., Scheff S.W., Ding Q., Chen Q., Butterfield D.A., et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 2005, 64(7):1152-1156.
133. Khan S.M., Bennett J.P. Development of mitochondrial gene replacement therapy. Journal of Bioenergetics and Biomembranes 2004, 36(4):387-393.
134. Kimberly W.T., Xia W., Rahmati T., Wolfe M.S., Selkoe D.J. The transmembrane aspartates in presenilin 1 and 2 are obligatory for gamma-secretase activity and amyloid beta-protein generation. Journal of Biological Chemistry 2000, 275(5):3173-3178.
135. Kish S.J., Mastrogiacomo F., Guttman M., Furukawa Y., Taanman J.W., Dozic S., et al. Decreased brain protein levels of cytochrome oxidase subunits in Alzheimer's disease and in hereditary spinocerebellar ataxia disorders: a nonspecific change?. Journal of Neurochemistry 1999, 72(2):700-707.
136. Kitamura Y., Shimohama S., Kamoshima W., Ota T., Matsuoka Y., Nomura Y., et al. Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease. Brain Research 1998, 780(2):260-269.
137. Kochl R., Hu X.W., Chan E.Y., Tooze S.A. Microtubules facilitate autophagosome formation and fusion of autophagosomes with endosomes. Traffic 2006, 7(2):129-145.
138. Kraepelin E. Psychiatrie. Ein Lehrbuch fur Studierende und Arzte. Klinishce Psychiatrie 1910, Verlag Johann Ambrosius Barth, Lepzig.
139. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127(6):1109-1122.
140. Lambert A.J., Wang B., Yardley J., Edwards J., Merry B.J. The effect of aging and caloric restriction on mitochondrial protein density and oxygen consumption. Experimental Gerontology 2004, 39(3):289-295.
141. Lassmann H., Bancher C., Breitschopf H., Wegiel J., Bobinski M., Jellinger K., et al. Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathologica 1995, 89(1):35-41.
142. Lauderback C.M., Hackett J.M., Huang F.F., Keller J.N., Szweda L.I., Markesbery W.R., et al. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: The role of Abeta1-42. Journal of Neurochemistry 2001, 78(2):413-416.
143. Lee V.M., Daughenbaugh R., Trojanowski J.Q. Microtubule stabilizing drugs for the treatment of Alzheimer's disease. Neurobiology of Aging 1994, 2(Suppl. 15):S87-S89.
144. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132(1):27-42.
145. Levy-Lahad E., Wasco W., Poorkaj P., Romano D.M., Oshima J., Pettingell W.H., et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995, 269(5226):973-977.
146. Levy E., Carman M.D., Fernandez-Madrid I.J., Power M.D., Lieberburg I., van Duinen S.G., et al. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 1990, 248(4959):1124-1126.
147. Li G., Faibushevich A., Turunen B.J., Yoon S.O., Georg G., Michaelis M.L., et al. Stabilization of the cyclin-dependent kinase 5 activator, p.35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons. Journal of Neurochemistry 2003, 84(2):347-362.
148. Li W.P., Chan W.Y., Lai H.W., Yew D.T. Terminal dUTP nick end labeling (TUNEL) positive cells in the different regions of the brain in normal aging and Alzheimer patients. Journal of Molecular Neuroscience 1997, 8(2):75-82.
149. Li Z., Okamoto K., Hayashi Y., Sheng M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 2004, 119(6):873-887.
150. Liang W.S., Reiman E.M., Valla J., Dunckley T., Beach T.G., Grover A., et al. Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(11):4441-4446.
151. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443(7113):787-795.
152. Lin M.T., Simon D.K., Ahn C.H., Kim L.M., Beal M.F. High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Human Molecular Genetics 2002, 11(2):133-145.
153. Liu Y., Ali S.M., Boge T.C., Georg G.I., Victory S., Zygmunt J., et al. A systematic SAR study of C10 modified paclitaxel analogues using a combinatorial approach. Combinatorial Chemistry & high Throughput Screening 2002, 5(1):39-48.
154. Lopez-Lluch G., Hunt N., Jones B., Zhu M., Jamieson H., Hilmer S., et al. Calorie restriction induces mitochondrial biogenesis and bioenergetic efficiency. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(6):1768-1773.
155. Lovell M.A., Markesbery W.R. Oxidatively modified RNA in mild cognitive impairment. Neurobiology of Disease 2008, 29(2):169-175.
156. Lu J., Wang K., Rodova M., Esteves R., Berry D.E.L., et al. Polymorphic variation in cytochrome oxidase subunit genes. Journal of Alzheimer's Disease 2010, 21(1):141-154.
157. Luft R. The development of mitochondrial medicine. Proceedings of the National Academy of Sciences of the United States of America 1994, 91(19):8731-8738.
158. MacAskill A.F., Atkin T.A., Kittler J.T. Mitochondrial trafficking and the provision of energy and calcium buffering at excitatory synapses. European Journal of Neuroscience 2010, 32(2):231-240.
159. Manczak M., Calkins M.J., Reddy P.H. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: Implications for neuronal damage. Human Molecular Genetics 2011, 20(13):2495-2509.
160. Manczak M., Mao P., Calkins M.J., Cornea A., Reddy A.P., Murphy M.P., et
161. Manczak M., Park B.S., Jung Y., Reddy P.H. Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: Implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Medicine 2004, 5(2):147-162.
162. Markesbery W.R., Lovell M.A. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiology of Aging 1998, 19(1):33-36.
163. Markesbery W.R., Lovell M.A. Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Archives of Neurology 2007, 64(7):954-956.
164. Masliah E., Hansen L., Mallory M., Albright T., Terry R.D. Abnormal brain spectrin immunoreactivity in sprouting neurons in Alzheimer disease. Neuroscience Letters 1991, 129(1):1-5.
165. Masliah E., Iimoto D.S., Saitoh T., Hansen L.A., Terry R.D. Increased immunoreactivity of brain spectrin in Alzheimer disease: a marker for synapse loss?. Brain Research 1990, 531(1-2):36-44.
166. Masliah E., Mallory M., Alford M., Tanaka S., Hansen L.A. Caspase dependent DNA fragmentation might be associated with excitotoxicity in Alzheimer disease. Journal of Neuropathology and Experimental Neurology 1998, 57(11):1041-1052.
167. Massaad C.A., Amin S.K., Hu L., Mei Y., Klann E., Pautler R.G. Mitochondrial superoxide contributes to blood flow and axonal transport deficits in the Tg2576 mouse model of Alzheimer's disease. PLoS One 2010, 5(5). e10561.
168. Matsuoka Y., Gray A.J., Hirata-Fukae C., Minami S.S., Waterhouse E.G., Mattson M.P., et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. Journal of Molecular Neuroscience 2007, 31(2):165-170.
169. Matsuoka Y., Jouroukhin Y., Gray A.J., Ma L., Hirata-Fukae C., Li H.F., et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. Journal of Pharmacology and Experimental Therapeutics 2008, 325(1):146-153.
170. Mattson M.P., Gleichmann M., Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron 2008, 60(5):748-766.
171. McManus M.J., Murphy M.P., Franklin J.L. The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease. Journal of Neuroscience 2011, 31(44):15703-15715.
172. Mecocci P., MacGarvey U., Beal M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Annals of Neurology 1994, 36(5):747-751.
173. Mecocci P., Polidori M.C., Cherubini A., Ingegni T., Mattioli P., Catani M., et al. Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Archives of Neurology 2002, 59(5):794-798.
174. Mecocci P., Polidori M.C., Ingegni T., Cherubini A., Chionne F., Cecchetti R., et al. Oxidative damage to DNA in lymphocytes from AD patients. Neurology 1998, 51(4):1014-1017.
175. Michaelis M.L., Dobrowsky R.T., Li G. Tau neurofibrillary pathology and microtubule stability. Journal of Molecular Neuroscience 2002, 19(3):289-293.
176. Migliore L., Fontana I., Trippi F., Colognato R., Coppede F., Tognoni G., et al. Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiology of Aging 2005, 26(5):567-573.
177. Miller E.R., Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Annals of Internal Medicine 2005, 142(1):37-46.
178. Miyasaka T., Sato S., Tatebayashi Y., Takashima A. Microtubule destruction induces tau liberation and its subsequent phosphorylation. FEBS Letters 2010, 584(14):3227-3232.
179. Moreira P.I., Cardoso S.M., Pereira C.M., Santos M.S., Oliveira C.R. Mitochondria as a therapeutic target in Alzheimer's disease and diabetes. CNS & Neurological Disorders Drug Targets 2009, 8(6):492-511.
180. Moreira P.I., Cardoso S.M., Santos M.S., Oliveira C.R. The key role of mitochondria in Alzheimer's disease. Journal of Alzheimer's Disease 2006, 9(2):101-110.
181. Morocz M., Kalman J., Juhasz A., Sinko I., McGlynn A.P., Downes C.S., et al. Elevated levels of oxidative DNA damage in lymphocytes from patients with Alzheimer's disease. Neurobiology of Aging 2002, 23(1):47-53.
182. Morris J.C., Storandt M., Miller J.P., McKeel D.W., Price J.L., Rubin E.H., et al. Mild cognitive impairment represents early-stage Alzheimer disease. Archives of Neurology 2001, 58(3):397-405.
183. Morten K.J., Ackrell B.A., Melov S. Mitochondrial reactive oxygen species in mice lacking superoxide dismutase 2: Attenuation via antioxidant treatment. Journal of Biological Chemistry 2006, 281(6):3354-3359.
184. Mosconi L., Berti V., Swerdlow R.H., Pupi A., Duara R., de Leon M. Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes. Human Genomics 2010, 4(3):170-193.
185. Mosconi L., Brys M., Switalski R., Mistur R., Glodzik L., Pirraglia E., et al. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(48):19067-19072.
186. Mosconi L., de Leon M., Murray J.E.L., Lu J., Javier E., et al. Reduced mitochondria cytochrome oxidase activity in adult children of mothers with Alzheimer's disease. Journal of Alzheimer's Disease 2011, 27(3):483-490.
187. Mosconi L., Glodzik L., Mistur R., McHugh P., Rich K.E., Javier E., et al. Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer's. Biological Psychiatry 2010, 68(10):913-921.
188. Mosconi L., Mistur R., Switalski R., Brys M., Glodzik L., Rich K., et al. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology 2009, 72(6):513-520.
189. Mosconi L., Rinne J.O., Tsui W.H., Berti V., Li Y., Wang H., et al. Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(13):5949-5954.
190. Nagy Z., Esiri M.M., LeGris M., Matthews P.M. Mitochondrial enzyme expression in the hippocampus in relation to Alzheimer-type pathology. Acta Neuropathologica 1999, 97(4):346-354.
191. Nisoli E., Tonello C., Cardile A., Cozzi V., Bracale R., Tedesco L., et al. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science 2005, 310(5746):314-317.
192. Nixon R.A. Autophagy, amyloidogenesis and Alzheimer disease. Journal of Cell Science 2007, 120(Pt 23):4081-4091.
193. Nixon R.A., Wegiel J., Kumar A., Yu W.H., Peterhoff C., Cataldo A., et al. Extensive involvement of autophagy in Alzheimer disease: An immuno-electron microscopy study. Journal of Neuropathology and Experimental Neurology 2005, 64(2):113-122.
194. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., et al. Oxidative damage is the earliest event in Alzheimer disease. Journal of Neuropathology and Experimental Neurology 2001, 60(8):759-767.
195. Nunomura A., Perry G., Pappolla M.A., Wade R., Hirai K., Chiba S., et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. Journal of Neuroscience 1999, 19(6):1959-1964.
196. Padurariu M., Ciobica A., Hritcu L., Stoica B., Bild W., Stefanescu C. Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease. Neuroscience Letters 2010, 469(1):6-10.
197. Panza F., Solfrizzi V., Seripa D., Imbimbo B.P., Pilotto A., Frisardi V. Peripheral antioxidant markers in mild cognitive impairment and its progression to dementia. Journal of Alzheimer's Disease 2010, 21(4):1179-1183.
198. Parker W.D., Filley C.M., Parks J.K. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 1990, 40(8):1302-1303.
199. Parker W.D., Parks J.K. Cytochrome c oxidase in Alzheimer's disease brain: Purification and characterization. Neurology 1995, 45(3 Pt 1):482-486.
200. Petersen R.B., Nunomura A., Lee H.G., Casadesus G., Perry G., Smith M.A., et al. Signal transduction cascades associated with oxidative stress in Alzheimer's disease. Journal of Alzheimer's Disease 2007, 11(2):143-152.
201. Peterson C., Vanderklish P., Seubert P., Cotman C., Lynch G. Increased spectrin proteolysis in fibroblasts from aged and Alzheimer donors. Neuroscience Letters 1991, 121(1-2):239-243.
202. Pigino G., Morfini G., Pelsman A., Mattson M.P., Brady S.T., Busciglio J. Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. Journal of Neuroscience 2003, 23(11):4499-4508.
203. Pratico D. Peripheral biomarkers of oxidative damage in Alzheimer's disease: The road ahead. Neurobiology of Aging 2005, 26(5):581-583.
204. Pratico D., Clark C.M., Liun F., Rokach J., Lee V.Y., Trojanowski J.Q. Increase of brain oxidative stress in mild cognitive impairment: A possible predictor of Alzheimer disease. Archives of Neurology 2002, 59(6):972-976.
205. Pratico D.V., M.Y.L., Trojanowski J.Q., Rokach J., Fitzgerald G.A. Increased F2-isoprostanes in Alzheimer's disease: Evidence for enhanced lipid peroxidation in vivo. FASEB Journal 1998, 12(15):1777-1783.
206. Qin W., Haroutunian V., Katsel P., Cardozo C.P., Ho L., Buxbaum J.D., et al. PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Archives of Neurology 2009, 66(3):352-361.
207. Quinzii C.M., DiMauro S., Hirano M. Human coenzyme Q10 deficiency. Neurochemical Research 2007, 32(4-5):723-727.
208. Ray P.D., Huang B.W., Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cellular Signalling 2012.
209. Reddy P.H. Mitochondrial medicine for aging and neurodegenerative diseases. Neuromolecular Medicine 2008, 10(4):291-315.
210. Reddy P.H., Shirendeb U.P. Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease. Biochimica et Biophysica Acta 2011, 1822(2):101-110.
211. Reddy P.H., Tripathi R., Troung Q., Tirumala K., Reddy T.P., Anekonda V., et al. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: Implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta 2012, 1822(5):639-649.
212. Redlich E. Über miliare Sklerosen der Hirnrinde bei seniler Atrophie. Jahrbiicherfar Psychiatrie und Neurologie 1898, 17:208-216.
213. Rinaldi P., Polidori M.C., Metastasio A., Mariani E., Mattioli P., Cherubini A., et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiology of Aging 2003, 24(7):915-919.
214. Risner M.E., Saunders A.M., Altman J.F., Ormandy G.C., Craft S., Foley I.M., et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics Journal 2006, 6(4):246-254.
215. Rohn T.T., Head E. Caspases as therapeutic targets in Alzheimer's disease: is it time to "cut" to the chase?. International Journal of Clinical and Experimental Pathology 2009, 2(2):108-118.
216. Rohn T.T., Head E., Nesse W.H., Cotman C.W., Cribbs D.H. Activation of caspase-8 in the Alzheimer's disease brain. Neurobiology of Disease 2001, 8(6):1006-1016.
217. Rohn T.T., Head E., Su J.H., Anderson A.J., Bahr B.A., Cotman C.W., et al. Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer's disease. American Journal of Pathology 2001, 158(1):189-198.
218. Rohn T.T., Rissman R.A., Davis M.C., Kim Y.E., Cotman C.W., Head E. Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain. Neurobiology of Disease 2002, 11(2):341-354.
219. Sandstrom P.A., Tebbey P.W., Van Cleave S., Buttke T.M. Lipid hydroperoxides induce apoptosis in T cells displaying a HIV-associated glutathione peroxidase deficiency. Journal of Biological Chemistry 1994, 269(2):798-801.
220. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. New England Journal of Medicine 1997, 336(17):1216-1222.
221. Santa-Maria I., Smith M.A., Perry G., Hernandez F., Avila J., Moreno F.J. Effect of quinones on microtubule polymerization: a link between oxidative stress and cytoskeletal alterations in Alzheimer's disease. Biochimica et Biophysica Acta 2005, 1740(3):472-480.
222. Santos R.X., Correia S.C., Wang X., Perry G., Smith M.A., Moreira P.I., et al. A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer's disease. Journal of Alzheimer's Disease 2010, 2(Suppl. 20):S401-S412.
223. Saraiva A.A., Borges M.M., Madeira M.D., Tavares M.A., Paula-Barbosa M.M. Mitochondrial abnormalities in cortical dendrites from patients with Alzheimer's disease. Journal of Submicroscopic Cytology 1985, 17(3):459-464.
224. Sayre L.M., Zelasko D.A., Harris P.L., Perry G., Salomon R.G., Smith M.A. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. Journal of Neurochemistry 1997, 68(5):2092-2097.
225. Selznick L.A., Holtzman D.M., Han B.H., Gokden M., Srinivasan A.N., Johnson E.M., et al. In situ immunodetection of neuronal caspase-3 activation in Alzheimer disease. Journal of Neuropathology and Experimental Neurology 1999, 58(9):1020-1026.
226. Senin U., Parnetti L., Barbagallo-Sangiorgi G., Bartorelli L., Bocola V., Capurso A., et al. Idebenone in senile dementia of Alzheimer type: a multicentre study. Archives of Gerontology and Geriatrics 1992, 15(3):249-260.
227. Sheng B., Wang X., Su B., Lee H.G., Casadesus G., Perry G., et al. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease. Journal of Neurochemistry 2012, 120(3):419-429.
228. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995, 375(6534):754-760.
229. Sheu K.F., Cooper A.J., Koike K., Koike M., Lindsay J.G., Blass J.P. Abnormality of the alpha-ketoglutarate dehydrogenase complex in fibroblasts from familial Alzheimer's disease. Annals of Neurology 1994, 35(3):312-318.
230. Shi C., Guo K., Yew D.T., Yao Z., Forster E.L., Wang H., et al. Effects of ageing and Alzheimer's disease on mitochondrial function of human platelets. Experimental Gerontology 2008, 43(6):589-594.
231. Shi Q., Xu H., Yu H., Zhang N., Ye Y., Estevez A.G., et al. Inactivation and reactivation of the mitochondrial alpha-ketoglutarate dehydrogenase complex. Journal of Biological Chemistry 2011, 286(20):17640-17648.
232. Shigenaga M.K., Hagen T.M., Ames B.N. Oxidative damage and mitochondrial decay in aging. Proceedings of the National Academy of Sciences of the United States of America 1994, 91(23):10771-10778.
233. Shimohama S. Apoptosis in Alzheimer's disease-an update. Apoptosis 2000, 5(1):9-16.
234. Shirendeb U.P., Calkins M.J., Manczak M., Anekonda V., Dufour B., McBride J.L., et al. Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease. Human Molecular Genetics 2012, 21(2):406-420.
235. Shiryaev N., Jouroukhin Y., Giladi E., Polyzoidou E., Grigoriadis N.C., Rosenmann H., et al. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiology of Disease 2009, 34(2):381-388.
236. Shiryaev N., Pikman R., Giladi E., Gozes I. Protection against tauopathy by the drug candidates NAP (Davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Current Pharmaceutical Design 2011, 17(25):2603-2612.
237. Silva D.F., Esteves A.R., Arduino D.M., Oliveira C.R., Cardoso S.M. Amyloid-beta-induced mitochondrial dysfunction impairs the autophagic lysosomal pathway in a tubulin dependent pathway. Journal of Alzheimer's Disease 2011, 26(3):565-581.
238. Silva D.F., Esteves A.R., Oliveira C.R., Cardoso S.M. Mitochondria: The common upstream driver of amyloid-beta and tau pathology in Alzheimer's disease. Current Alzheimer Research 2011, 8(5):563-572.
239. Simonian N.A., Hyman B.T. Functional alterations in Alzheimer's disease: Diminution of cytochrome oxidase in the hippocampal formation. Journal of Neuropathology and Experimental Neurology 1993, 52(6):580-585.
240. Singh M., Nam D.T., Arseneault M., Ramassamy C. Role of by-products of lipid oxidation in Alzheimer's disease brain: A focus on acrolein. Journal of Alzheimer's Disease 2010, 21(3):741-756.
241. Skulachev V.P. Role of uncoupled and non-coupled oxidations in maintenance of safely low levels of oxygen and its one-electron reductants. Quarterly Reviews of Biophysics 1996, 29(2):169-202.
242. Smale G., Nichols N.R., Brady D.R., Finch C.E., Horton W.E. Evidence for apoptotic cell death in Alzheimer's disease. Experimental Neurology 1995, 133(2):225-230.
243. Smith C.D., Carney J.M., Starke-Reed P.E., Oliver C.N., Stadtman E.R., Floyd R.A., et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 1991, 88(23):10540-10543.
244. Smith M.A., Rottkamp C.A., Nunomura A., Raina A.K., Perry G. Oxidative stress in Alzheimer's disease. Biochimica et Biophysica Acta 2000, 1502(1):139-144.
245. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dementia 2011, 7(3):280-292.
246. Stadelmann C., Deckwerth T.L., Srinivasan A., Bancher C., Bruck W., Jellinger K., et al. Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. American Journal of Pathology 1999, 155(5):1459-1466.
247. Stamer K., Vogel R., Thies E., Mandelkow E., Mandelkow E.M. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. Journal of Cell Biology 2002, 156(6):1051-1063.
248. Sterky F.H., Lee S., Wibom R., Olson L., Larsson N.G. Impaired mitochondrial transport and Parkin-independent degeneration of respiratory chain-deficient dopamine neurons in vivo. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(31):12937-12942.
249. Su B., Wang X., Bonda D., Perry G., Smith M., Zhu X. Abnormal mitochondrial dynamics-a novel therapeutic target for Alzheimer's disease?. Molecular Neurobiology 2010, 41(2-3):87-96.
250. Su J.H., Anderson A.J., Cummings B.J., Cotman C.W. Immunohistochemical evidence for apoptosis in Alzheimer's disease. Neuroreport 1994, 5(18):2529-2533.
251. Su J.H., Deng G., Cotman C.W. Bax protein expression is increased in Alzheimer's brain: correlations with DNA damage, Bcl-2 expression, and brain pathology. Journal of Neuropathology and Experimental Neurology 1997, 56(1):86-93.
252. Subramaniam R., Roediger F., Jordan B., Mattson M.P., Keller J.N., Waeg G., et al. The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. Journal of Neurochemistry 1997, 69(3):1161-1169.
253. Sullivan P.G., Brown M.R. Mitochondrial aging and dysfunction in Alzheimer's disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2005, 29(3):407-410.
254. Sullivan P.G., Rippy N.A., Dorenbos K., Concepcion R.C., Agarwal A.K., Rho J.M. The ketogenic diet increases mitochondrial uncoupling protein levels and activity. Annals of Neurology 2004, 55(4):576-580.
255. Sultana R., Butterfield D.A. Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment. Journal of Bioenergetics and Biomembranes 2009, 41(5):441-446.
256. Sultana R., Perluigi M., Newman S.F., Pierce W.M., Cini C., Coccia R., et al. Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer's disease. Antioxidants & Redox Signaling 2010, 12(3):327-336.
257. Sung S., Yao Y., Uryu K., Yang H., Lee V.M., Trojanowski J.Q., et al. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB Journal 2004, 18(2):323-325.
258. Swerdlow R., Marcus D.M., Landman J., Harooni M., Freedman M.L. Brain glucose and ketone body metabolism in patients with Alzheimer's disease. Clinical Research 1989, 37(2):461A.
259. Swerdlow, R. H. Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases. Curr Pharm Des, 17(31), 3356-3373.
260. Swerdlow R.H. Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging?. Neurobiology of Aging 2007, 28(10):1465-1480.
261. Swerdlow R.H. Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies. Journal of Neuroscience Research 2007, 85(15):3416-3428.
262. Swerdlow R.H. Treating neurodegeneration by modifying mitochondria: potential solutions to a "complex" problem. Antioxidants & Redox Signaling 2007, 9(10):1591-1603.
263. Swerdlow R.H. Mitochondrial medicine and the neurodegenerative mitochondriopathies. Pharmaceuticals 2009, 2:150-167.
264. Swerdlow R.H. Brain aging, Alzheimer's disease, and mitochondria. Biochimica et Biophysica Acta 2011, 1812(12):1630-1639.
265. Swerdlow R.H. Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases. Current Pharmaceutical Design 2011, 17(31):3356-3373.
266. Swerdlow R.H. Mitochondria and cell bioenergetics: Increasingly recognized components and a possible etiologic cause of Alzheimer's disease. Antioxid Redox Signal 2012, 16(12):1434-1455.
267. Swerdlow R.H., Burns J.M., Khan S.M. The Alzheimer's disease mitochondrial cascade hypothesis. Journal of Alzheimer's Disease 2010, 2(Suppl. 20):S265-S279.
268. Swerdlow R.H., Kish S.J. Mitochondria in Alzheimer's disease. International Review of Neurobiology 2002, 53:341-385.
269. Taylor R.W., Chinnery P.F., Turnbull D.M., Lightowlers R.N. Selective inhibition of mutant human mitochondrial DNA replication in vitro by peptide nucleic acids. Nature Genetics 1997, 15(2):212-215.
270. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Annals of Neurology 1991, 30(4):572-580.
271. Thal L.J., Grundman M., Berg J., Ernstrom K., Margolin R., Pfeiffer E., et al. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology 2003, 61(11):1498-1502.
272. Thies W., Bleiler L. 2011 Alzheimer's disease facts and figures. Alzheimer's Dementia 2011, 7(2):208-244.
273. Torres L.L., Quaglio N.B., de Souza G.T., Garcia R.T., Dati L.M., Moreira W.L., et al. Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease. Journal of Alzheimer's Disease 2011, 26(1):59-68.
274. Torroni A., Huoponen K., Francalacci P., Petrozzi M., Morelli L., Scozzari R., et al. Classification of European mtDNAs from an analysis of three European populations. Genetics 1996, 144(4):1835-1850.
275. Trimmer P.A., Borland M.K. Differentiated Alzheimer's disease transmitochondrial cybrid cell lines exhibit reduced organelle movement. Antioxidants & Redox Signaling 2005, 7(9-10):1101-1109.
276. Troncoso J.C., Sukhov R.R., Kawas C.H., Koliatsos V.E. In situ labeling of dying cortical neurons in normal aging and in Alzheimer's disease: correlations with senile plaques and disease progression. Journal of Neuropathology and Experimental Neurology 1996, 55(11):1134-1142.
277. Turrens J.F., Boveris A. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochemical Journal 1980, 191(2):421-427.
278. Valla J., Schneider L., Niedzielko T., Coon K.D., Caselli R., Sabbagh M.N., et al. Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. Mitochondrion 2006, 6(6):323-330.
279. Varadi A., Johnson-Cadwell L.I., Cirulli V., Yoon Y., Allan V.J., Rutter G.A. Cytoplasmic dynein regulates the subcellular distribution of mitochondria by controlling the recruitment of the fission factor dynamin-related protein-1. Journal of Cell Science 2004, 117(Pt 19):4389-4400.
280. Vitte J., Michel B.F., Bongrand P., Gastaut J.L. Oxidative stress level in circulating neutrophils is linked to neurodegenerative diseases. Journal of Clinical Immunology 2004, 24(6):683-692.
281. Vulih-Shultzman I., Pinhasov A., Mandel S., Grigoriadis N., Touloumi O., Pittel Z., et al. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. Journal of Pharmacology and Experimental Therapeutics 2007, 323(2):438-449.
282. Walsh D.M., Selkoe D.J. A beta oligomers - A decade of discovery. Journal of Neurochemistry 2007, 101(5):1172-1184.
283. Wang X., Su B., Fujioka H., Zhu X. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients. American Journal of Pathology 2008, 173(2):470-482.
284. Wang X., Su B., Lee H.G., Li X., Perry G., Smith M.A., et al. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. Journal of Neuroscience 2009, 29(28):9090-9103.
285. Wang X., Su B., Siedlak S.L., Moreira P.I., Fujioka H., Wang Y., et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(49):19318-19323.
286. Wenz T., Williams S.L., Bacman S.R., Moraes C.T. Emerging therapeutic approaches to mitochondrial diseases. Developmental Disabilities Research Reviews 2010, 16(2):219-229.
287. Westermann B. Nitric oxide links mitochondrial fission to Alzheimer's disease. Science Signaling 2009, 2(69). pe29.
288. Weyer G., Babej-Dolle R.M., Hadler D., Hofmann S., Herrmann W.M. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. Neuropsychobiology 1997, 36(2):73-82.
289. Wischik C.M., Bentham P., Wischik D.J., Seng K.M. Tau aggregation inhibitor (TAI) therapy with rember arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimer's and Dementia 2008, 4:T167.
290. Wolfe M.S., Xia W., Ostaszewski B.L., Diehl T.S., Kimberly W.T., Selkoe D.J. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 1999, 398(6727):513-517.
291. Xie R., Nguyen S., McKeehan W.L., Liu L. Acetylated microtubules are required for fusion of autophagosomes with lysosomes. BMC Cell Biology 2010, 11:89.
292. Yankner B.A., Dawes L.R., Fisher S., Villa-Komaroff L., Oster-Granite M.L., Neve R.L. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 1989, 245(4916):417-420.
293. Yates C.M., Butterworth J., Tennant M.C., Gordon A. Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias. Journal of Neurochemistry 1990, 55(5):1624-1630.
294. Yoon Y., Krueger E.W., Oswald B.J., McNiven M.A. The mitochondrial protein hFis1 regulates mitochondrial fission in mammalian cells through an interaction with the dynamin-like protein DLP1. Molecular Cell Biology 2003, 23(15):5409-5420.
295. Yu W.H., Cuervo A.M., Kumar A., Peterhoff C.M., Schmidt S.D., Lee J.H., et al. Macroautophagy-a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease. Journal of Cell Biology 2005, 171(1):87-98.
296. Yu W.H., Kumar A., Peterhoff C., Shapiro Kulnane L., Uchiyama Y., Lamb B.T., et al. Autophagic vacuoles are enriched in amyloid precursor protein-secretase activities: implications for beta-amyloid peptide over-production and localization in Alzheimer's disease. International Journal of Biochemistry & Cell Biology 2004, 36(12):2531-2540.
297. Zhang S., Hedskog L., Petersen C.A., Winblad B., Ankarcrona M. Dimebon (latrepirdine) enhances mitochondrial function and protects neuronal cells from death. Journal of Alzheimer's Disease 2010, 21(2):389-402.
298. Zhu X., Raina A.K., Perry G., Smith M.A. Alzheimer's disease: the two-hit hypothesis. Lancet Neurology 2004, 3(4):219-226.